ZA200410407B - Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders - Google Patents
Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders Download PDFInfo
- Publication number
- ZA200410407B ZA200410407B ZA200410407A ZA200410407A ZA200410407B ZA 200410407 B ZA200410407 B ZA 200410407B ZA 200410407 A ZA200410407 A ZA 200410407A ZA 200410407 A ZA200410407 A ZA 200410407A ZA 200410407 B ZA200410407 B ZA 200410407B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- dihydro
- alkyl
- dimethyl
- group
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 25
- 208000017520 skin disease Diseases 0.000 title claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 146
- 229910052799 carbon Inorganic materials 0.000 claims description 125
- 125000003545 alkoxy group Chemical group 0.000 claims description 64
- 229910052739 hydrogen Inorganic materials 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 54
- 125000005842 heteroatom Chemical group 0.000 claims description 53
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 50
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 50
- 125000000623 heterocyclic group Chemical group 0.000 claims description 48
- 150000001875 compounds Chemical class 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 38
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 125000003107 substituted aryl group Chemical group 0.000 claims description 26
- 125000004001 thioalkyl group Chemical group 0.000 claims description 25
- 206010000496 acne Diseases 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 22
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 19
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 150000001721 carbon Chemical class 0.000 claims description 13
- 239000002207 metabolite Substances 0.000 claims description 12
- 239000000651 prodrug Substances 0.000 claims description 12
- 229940002612 prodrug Drugs 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 206010020112 Hirsutism Diseases 0.000 claims description 8
- 230000003750 conditioning effect Effects 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000002252 acyl group Chemical group 0.000 claims description 6
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 150000001555 benzenes Chemical group 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 208000028257 Joubert syndrome with oculorenal defect Diseases 0.000 claims description 3
- 238000002657 hormone replacement therapy Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000002379 progesterone receptor modulator Substances 0.000 claims description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 37
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 229940011871 estrogen Drugs 0.000 claims 4
- 239000000262 estrogen Substances 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 229940088597 hormone Drugs 0.000 claims 3
- JWRMZXFZQZVKSD-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(C#N)=C1 JWRMZXFZQZVKSD-UHFFFAOYSA-N 0.000 claims 2
- CUQLFUMXNAKZSH-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)benzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(C#N)=C1 CUQLFUMXNAKZSH-UHFFFAOYSA-N 0.000 claims 2
- RILXTHFMVLBOPN-UHFFFAOYSA-N 3-(8-bromo-4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=C(Br)C=C1C1=CC(F)=CC(C#N)=C1 RILXTHFMVLBOPN-UHFFFAOYSA-N 0.000 claims 2
- YLRADUODZWLKHG-UHFFFAOYSA-N 3-fluoro-5-(8-fluoro-4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)benzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=C(F)C=C1C1=CC(F)=CC(C#N)=C1 YLRADUODZWLKHG-UHFFFAOYSA-N 0.000 claims 2
- FEWVQKWESAUNPQ-UHFFFAOYSA-N 4,4-dimethyl-6-(3-nitrophenyl)-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC([N+]([O-])=O)=C1 FEWVQKWESAUNPQ-UHFFFAOYSA-N 0.000 claims 2
- OEVOYVHAFYXKNX-UHFFFAOYSA-N 4-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)furan-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=COC(C#N)=C1 OEVOYVHAFYXKNX-UHFFFAOYSA-N 0.000 claims 2
- UCEMKOZZXFXATD-UHFFFAOYSA-N 4-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CSC(C#N)=C1 UCEMKOZZXFXATD-UHFFFAOYSA-N 0.000 claims 2
- JSOJTUILYANJMW-UHFFFAOYSA-N 4-benzyl-6-(3-chlorophenyl)-4-methyl-1h-3,1-benzoxazine-2-thione Chemical compound O1C(=S)NC2=CC=C(C=3C=C(Cl)C=CC=3)C=C2C1(C)CC1=CC=CC=C1 JSOJTUILYANJMW-UHFFFAOYSA-N 0.000 claims 2
- MQYRSOFJNHXZHN-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1-ethylpyrrole-2-carbonitrile Chemical compound CCN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 MQYRSOFJNHXZHN-UHFFFAOYSA-N 0.000 claims 2
- HYELXXFFGVQXLM-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1h-pyrrole-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)N1 HYELXXFFGVQXLM-UHFFFAOYSA-N 0.000 claims 2
- JXEZBFHBHFDRCM-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-4-methylthiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1C JXEZBFHBHFDRCM-UHFFFAOYSA-N 0.000 claims 2
- YULOLNRYBCOJDS-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-4-propylthiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1CCC YULOLNRYBCOJDS-UHFFFAOYSA-N 0.000 claims 2
- XSBJYXLVQYKJTL-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)S1 XSBJYXLVQYKJTL-UHFFFAOYSA-N 0.000 claims 2
- IUJHXSNSAUOSSH-UHFFFAOYSA-N 6-(2-chlorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC=C1Cl IUJHXSNSAUOSSH-UHFFFAOYSA-N 0.000 claims 2
- WYHOTGLZCWQZME-UHFFFAOYSA-N 6-(3-bromophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(Br)=C1 WYHOTGLZCWQZME-UHFFFAOYSA-N 0.000 claims 2
- IUQHQDMKFBMQME-UHFFFAOYSA-N 6-(3-chloro-4-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C(Cl)=C1 IUQHQDMKFBMQME-UHFFFAOYSA-N 0.000 claims 2
- HWFFFZIEYMMDDC-UHFFFAOYSA-N 6-(3-chlorophenyl)-4,4-diethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(CC)(CC)OC(=S)NC2=CC=C1C1=CC=CC(Cl)=C1 HWFFFZIEYMMDDC-UHFFFAOYSA-N 0.000 claims 2
- XCHOFVZQFUVVEB-UHFFFAOYSA-N 6-(3-chlorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(Cl)=C1 XCHOFVZQFUVVEB-UHFFFAOYSA-N 0.000 claims 2
- NAQUDAIOMWNXJF-UHFFFAOYSA-N 6-(3-fluorophenyl)-4-methyl-1,4-dihydro-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)OC(=S)NC2=CC=C1C1=CC=CC(F)=C1 NAQUDAIOMWNXJF-UHFFFAOYSA-N 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 210000004696 endometrium Anatomy 0.000 claims 2
- 230000012173 estrus Effects 0.000 claims 2
- LAQPNDIUHRHNCV-UHFFFAOYSA-N isophthalonitrile Chemical compound N#CC1=CC=CC(C#N)=C1 LAQPNDIUHRHNCV-UHFFFAOYSA-N 0.000 claims 2
- 201000010260 leiomyoma Diseases 0.000 claims 2
- 206010027191 meningioma Diseases 0.000 claims 2
- 230000002632 myometrial effect Effects 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- JHWNSFIRRIBDRF-UHFFFAOYSA-N tert-butyl 2-cyano-5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)pyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 JHWNSFIRRIBDRF-UHFFFAOYSA-N 0.000 claims 2
- GSXCEVHRIVLFJV-UHFFFAOYSA-N thiophene-3-carbonitrile Chemical compound N#CC=1C=CSC=1 GSXCEVHRIVLFJV-UHFFFAOYSA-N 0.000 claims 2
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims 1
- VMRFICRSRPCJAO-UHFFFAOYSA-N 1-methyl-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclobutane]-6-yl)pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC23CCC3)C2=C1 VMRFICRSRPCJAO-UHFFFAOYSA-N 0.000 claims 1
- JTUBUTWMKWNMTE-UHFFFAOYSA-N 1-methyl-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclopentane]-6-yl)pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC23CCCC3)C2=C1 JTUBUTWMKWNMTE-UHFFFAOYSA-N 0.000 claims 1
- HFXYEKNIBXVEDM-UHFFFAOYSA-N 1-methyl-5-[2-sulfanylidene-4,4-bis(trifluoromethyl)-1h-3,1-benzoxazin-6-yl]pyrrole-2-carbonitrile Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C(F)(F)F)C(F)(F)F)C2=C1 HFXYEKNIBXVEDM-UHFFFAOYSA-N 0.000 claims 1
- DCBOJAHTRJNPIJ-UHFFFAOYSA-N 2-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-3-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C=1SC=CC=1C#N DCBOJAHTRJNPIJ-UHFFFAOYSA-N 0.000 claims 1
- LTTWZTLIENERDL-UHFFFAOYSA-N 2-[6-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)pyridin-2-yl]acetonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(CC#N)=N1 LTTWZTLIENERDL-UHFFFAOYSA-N 0.000 claims 1
- GMQRDVATRSGMLF-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-4-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(C#N)=CC=C1F GMQRDVATRSGMLF-UHFFFAOYSA-N 0.000 claims 1
- CTTIMHOODJRMMQ-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-methoxybenzonitrile Chemical compound COC1=CC(C#N)=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 CTTIMHOODJRMMQ-UHFFFAOYSA-N 0.000 claims 1
- NGXWFLCNLTYJKI-UHFFFAOYSA-N 3-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-5-methylbenzonitrile Chemical compound CC1=CC(C#N)=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 NGXWFLCNLTYJKI-UHFFFAOYSA-N 0.000 claims 1
- HDYOFEAGTBBGEN-UHFFFAOYSA-N 3-chloro-5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)benzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(Cl)=CC(C#N)=C1 HDYOFEAGTBBGEN-UHFFFAOYSA-N 0.000 claims 1
- XURBBVPMTVGZEP-UHFFFAOYSA-N 3-fluoro-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)benzonitrile Chemical compound FC1=CC(C#N)=CC(C=2C=C3C4(CCCCC4)OC(=S)NC3=CC=2)=C1 XURBBVPMTVGZEP-UHFFFAOYSA-N 0.000 claims 1
- COIUOECSBDDSNQ-UHFFFAOYSA-N 4,4-diethyl-6-(3-nitrophenyl)-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(CC)(CC)OC(=S)NC2=CC=C1C1=CC=CC([N+]([O-])=O)=C1 COIUOECSBDDSNQ-UHFFFAOYSA-N 0.000 claims 1
- DCXHYBSZULGYNI-UHFFFAOYSA-N 4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=CC=C2C(C)(C)OC(=S)NC2=C1 DCXHYBSZULGYNI-UHFFFAOYSA-N 0.000 claims 1
- YXZAVJPXYUAVKV-UHFFFAOYSA-N 4-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)thiophene-2-carbonitrile Chemical compound O1C(=S)NC2=CC=C(C=3C=C(SC=3)C#N)C=C2C21CCCCC2 YXZAVJPXYUAVKV-UHFFFAOYSA-N 0.000 claims 1
- VSPMRIXKBGUPJW-UHFFFAOYSA-N 4-butyl-5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)thiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1CCCC VSPMRIXKBGUPJW-UHFFFAOYSA-N 0.000 claims 1
- UKMZDGICTYHTEO-UHFFFAOYSA-N 4-methyl-5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)thiophene-2-carbonitrile Chemical compound C1=C(C#N)SC(C=2C=C3C4(CCCCC4)OC(=S)NC3=CC=2)=C1C UKMZDGICTYHTEO-UHFFFAOYSA-N 0.000 claims 1
- KBUBDEWGNXRLKX-UHFFFAOYSA-N 5-(2-sulfanylidenespiro[1h-3,1-benzoxazine-4,1'-cyclohexane]-6-yl)thiophene-2-carbonitrile Chemical compound O1C(=S)NC2=CC=C(C=3SC(=CC=3)C#N)C=C2C21CCCCC2 KBUBDEWGNXRLKX-UHFFFAOYSA-N 0.000 claims 1
- XHLKPIQEIXNOQX-UHFFFAOYSA-N 5-(4,4-diethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile Chemical compound C1=C2C(CC)(CC)OC(=S)NC2=CC=C1C1=CC=C(C#N)N1C XHLKPIQEIXNOQX-UHFFFAOYSA-N 0.000 claims 1
- BCDNJBDJBGOTIA-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1h-pyrrole-2-carbothioamide Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C(N)=S)N1 BCDNJBDJBGOTIA-UHFFFAOYSA-N 0.000 claims 1
- QLNYJNLJIJPEAO-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-2-fluorobenzonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C(C#N)=C1 QLNYJNLJIJPEAO-UHFFFAOYSA-N 0.000 claims 1
- NUQMIQUEODQESK-UHFFFAOYSA-N 5-(4,4-dimethyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)furan-2-carbonitrile Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)O1 NUQMIQUEODQESK-UHFFFAOYSA-N 0.000 claims 1
- OZHNXRYXILKKOW-UHFFFAOYSA-N 5-(4-ethyl-4-methyl-2-sulfanylidene-1h-3,1-benzoxazin-6-yl)-1-methylpyrrole-2-carbonitrile Chemical compound C1=C2C(CC)(C)OC(=S)NC2=CC=C1C1=CC=C(C#N)N1C OZHNXRYXILKKOW-UHFFFAOYSA-N 0.000 claims 1
- WVQKUAAPNOSAJW-UHFFFAOYSA-N 6-(2,3-difluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC(F)=C1F WVQKUAAPNOSAJW-UHFFFAOYSA-N 0.000 claims 1
- GQLJJGUGKUYGRM-UHFFFAOYSA-N 6-(2-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=CC=C1F GQLJJGUGKUYGRM-UHFFFAOYSA-N 0.000 claims 1
- SMBQGFBYNMMQJM-UHFFFAOYSA-N 6-(3,4-difluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C(F)=C1 SMBQGFBYNMMQJM-UHFFFAOYSA-N 0.000 claims 1
- KTBKDGMHHINKLK-UHFFFAOYSA-N 6-(3,5-difluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(F)=C1 KTBKDGMHHINKLK-UHFFFAOYSA-N 0.000 claims 1
- BUGHELVCJWKCPY-UHFFFAOYSA-N 6-(3-bromo-5-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(Br)=C1 BUGHELVCJWKCPY-UHFFFAOYSA-N 0.000 claims 1
- WUJWTXWFRXJYKR-UHFFFAOYSA-N 6-(3-bromo-5-methylphenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound CC1=CC(Br)=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 WUJWTXWFRXJYKR-UHFFFAOYSA-N 0.000 claims 1
- JGZLNKUOAMAIAG-UHFFFAOYSA-N 6-(3-chloro-5-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(Cl)=C1 JGZLNKUOAMAIAG-UHFFFAOYSA-N 0.000 claims 1
- YBBTTYFZWTXGQD-UHFFFAOYSA-N 6-(3-chlorophenyl)-4-methyl-4-phenyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C=3C=CC=CC=3)OC(=S)NC2=CC=C1C1=CC=CC(Cl)=C1 YBBTTYFZWTXGQD-UHFFFAOYSA-N 0.000 claims 1
- UMQGDADSFKJZKD-UHFFFAOYSA-N 6-(3-methoxyphenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound COC1=CC=CC(C=2C=C3C(C)(C)OC(=S)NC3=CC=2)=C1 UMQGDADSFKJZKD-UHFFFAOYSA-N 0.000 claims 1
- PIVCHRZUHMHWMD-UHFFFAOYSA-N 6-(4-fluorophenyl)-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC=C(F)C=C1 PIVCHRZUHMHWMD-UHFFFAOYSA-N 0.000 claims 1
- FXVPGONKQHRTRT-UHFFFAOYSA-N 6-[3-bromo-5-(trifluoromethoxy)phenyl]-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(Br)=CC(OC(F)(F)F)=C1 FXVPGONKQHRTRT-UHFFFAOYSA-N 0.000 claims 1
- KWEKPTTVUMVEHM-UHFFFAOYSA-N 6-[3-fluoro-5-(trifluoromethyl)phenyl]-4,4-dimethyl-1h-3,1-benzoxazine-2-thione Chemical compound C1=C2C(C)(C)OC(=S)NC2=CC=C1C1=CC(F)=CC(C(F)(F)F)=C1 KWEKPTTVUMVEHM-UHFFFAOYSA-N 0.000 claims 1
- LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 10
- 208000035475 disorder Diseases 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 229940095745 sex hormone and modulator of the genital system progesterone receptor modulator Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010065701 Dermatillomania Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000009675 Perioral Dermatitis Diseases 0.000 description 1
- 208000001818 Pseudofolliculitis barbae Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010040849 Skin fissures Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Birds (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39188502P | 2002-06-25 | 2002-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200410407B true ZA200410407B (en) | 2007-07-25 |
Family
ID=30000769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200410407A ZA200410407B (en) | 2002-06-25 | 2004-12-23 | Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7268149B2 (ko) |
| EP (1) | EP1531824A4 (ko) |
| JP (1) | JP2005535628A (ko) |
| KR (1) | KR20050013627A (ko) |
| CN (1) | CN1665510A (ko) |
| AR (1) | AR040644A1 (ko) |
| AU (1) | AU2003245657A1 (ko) |
| BR (1) | BR0312039A (ko) |
| CA (1) | CA2489815A1 (ko) |
| CO (1) | CO5680439A2 (ko) |
| CR (1) | CR7608A (ko) |
| EC (1) | ECSP055572A (ko) |
| IL (1) | IL165397A0 (ko) |
| MX (1) | MXPA04012420A (ko) |
| NO (1) | NO20045214L (ko) |
| RU (1) | RU2005101625A (ko) |
| TW (1) | TW200400950A (ko) |
| WO (1) | WO2004000230A2 (ko) |
| ZA (1) | ZA200410407B (ko) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6391907B1 (en) | 1999-05-04 | 2002-05-21 | American Home Products Corporation | Indoline derivatives |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
| CA2489813A1 (en) * | 2002-06-25 | 2003-12-31 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| ATE409699T1 (de) * | 2004-04-08 | 2008-10-15 | Wyeth Corp | Verfahren zur minimierung von thioamidverunreinigungen |
| WO2005100346A1 (en) * | 2004-04-08 | 2005-10-27 | Wyeth | Thioamide derivatives as progesterone receptor modulators |
| AU2005237520B2 (en) * | 2004-04-27 | 2012-01-19 | Wyeth | Purification of progesterone receptor modulators |
| MXPA06012402A (es) * | 2004-04-27 | 2007-01-17 | Wyeth Corp | Carbamato y tiocarbamato biarilos ciclicos que contienen cianopirrol y metodos para preparar los mismos. |
| US20060009428A1 (en) * | 2004-07-07 | 2006-01-12 | Wyeth | Cyclic progestin regimens and kits |
| PT1778710E (pt) * | 2004-08-13 | 2012-04-12 | Wyeth Llc | Derivados de tanaproget, metabolitos e suas utilizações |
| JP2008510722A (ja) | 2004-08-20 | 2008-04-10 | ワイス | プロゲステロン受容体構造 |
| BRPI0610431A2 (pt) | 2005-04-28 | 2012-10-23 | Wyeth Corp | composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico |
| EP1874278B1 (en) * | 2005-04-28 | 2009-06-24 | Wyeth | Compositions containing micronized tanaproget |
| MX2007013469A (es) * | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| DE602006012972D1 (de) * | 2005-04-28 | 2010-04-29 | Wyeth Corp | Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung |
| WO2006116498A2 (en) * | 2005-04-28 | 2006-11-02 | Wyeth | Purified form of tanaproget |
| JP5339903B2 (ja) * | 2005-06-09 | 2013-11-13 | ワイス・エルエルシー | エチニルエストラジオールを含むタナプロゲット組成物 |
| MX2009006818A (es) * | 2006-12-22 | 2009-07-02 | Hoffmann La Roche | Procesos para la preparacion de (3r,4r)-n-(4-clorofenil)-1-(2,2-di fluoroetil)-n'-[2-fluoro-4-(2-oxo-1(2h)piridinil)fenil]-3,4-pirro dinadicarboxamida. |
| AU2008341138A1 (en) * | 2007-12-20 | 2009-07-02 | Teva Women's Health, Inc. | Dosage regimens and pharmaceutical compositions and packages for emergency contraception |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| EP2664325A1 (en) * | 2012-05-16 | 2013-11-20 | PregLem S.A. | Methods for preventing or treating androgen mediated diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1985000519A1 (en) | 1983-07-29 | 1985-02-14 | Duke University | Method of treating androgen-related disorders |
| GB2310660A (en) | 1996-03-01 | 1997-09-03 | Merck & Co Inc | Benzoxazinone oxytocin receptor antagonists |
| IL142598A0 (en) * | 1998-10-23 | 2002-03-10 | Aventis Pharma Gmbh | Preparations for topical application of substances having antiandrogenic effect |
| US6355648B1 (en) * | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| US6509334B1 (en) | 1999-05-04 | 2003-01-21 | American Home Products Corporation | Cyclocarbamate derivatives as progesterone receptor modulators |
| US6407101B1 (en) * | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| EP1206761B1 (en) | 1999-08-26 | 2007-10-03 | Automotive Systems Laboratory Inc. | Magnetic sensor |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| TR200200507T2 (tr) * | 1999-08-27 | 2002-10-21 | Ligand Pharmaceuticals Inc | Androjen reseptörü modülatör bileşikleri ve metotları |
| US7119207B2 (en) * | 2000-04-10 | 2006-10-10 | Pfizer Inc | Benzoamide piperidine containing compounds and related compounds |
| YU73902A (sh) | 2000-04-10 | 2005-09-19 | Pfizer Products Inc. | Jedinjenja koja sadrže benzoamid-piperidin i srodna jedinjenja |
| UA73119C2 (en) * | 2000-04-19 | 2005-06-15 | American Home Products Corpoir | Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors |
-
2003
- 2003-06-23 AU AU2003245657A patent/AU2003245657A1/en not_active Abandoned
- 2003-06-23 JP JP2004516187A patent/JP2005535628A/ja active Pending
- 2003-06-23 CA CA002489815A patent/CA2489815A1/en not_active Abandoned
- 2003-06-23 AR AR20030102239A patent/AR040644A1/es not_active Application Discontinuation
- 2003-06-23 RU RU2005101625/04A patent/RU2005101625A/ru not_active Application Discontinuation
- 2003-06-23 WO PCT/US2003/019860 patent/WO2004000230A2/en not_active Application Discontinuation
- 2003-06-23 IL IL16539703A patent/IL165397A0/xx unknown
- 2003-06-23 MX MXPA04012420A patent/MXPA04012420A/es unknown
- 2003-06-23 TW TW092116986A patent/TW200400950A/zh unknown
- 2003-06-23 US US10/601,968 patent/US7268149B2/en not_active Expired - Fee Related
- 2003-06-23 KR KR10-2004-7021150A patent/KR20050013627A/ko not_active Application Discontinuation
- 2003-06-23 CN CN038151944A patent/CN1665510A/zh active Pending
- 2003-06-23 EP EP03739286A patent/EP1531824A4/en not_active Withdrawn
- 2003-06-23 BR BR0312039-2A patent/BR0312039A/pt not_active IP Right Cessation
-
2004
- 2004-11-29 NO NO20045214A patent/NO20045214L/no not_active Application Discontinuation
- 2004-12-08 CR CR7608A patent/CR7608A/es not_active Application Discontinuation
- 2004-12-23 ZA ZA200410407A patent/ZA200410407B/en unknown
-
2005
- 2005-01-20 CO CO05004456A patent/CO5680439A2/es not_active Application Discontinuation
- 2005-01-25 EC EC2005005572A patent/ECSP055572A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004000230A2 (en) | 2003-12-31 |
| WO2004000230A3 (en) | 2004-04-29 |
| MXPA04012420A (es) | 2005-04-19 |
| CA2489815A1 (en) | 2003-12-31 |
| RU2005101625A (ru) | 2005-06-27 |
| CO5680439A2 (es) | 2006-09-29 |
| ECSP055572A (es) | 2005-04-18 |
| US7268149B2 (en) | 2007-09-11 |
| IL165397A0 (en) | 2006-01-15 |
| EP1531824A4 (en) | 2005-09-21 |
| AU2003245657A1 (en) | 2004-01-06 |
| AR040644A1 (es) | 2005-04-13 |
| BR0312039A (pt) | 2005-06-28 |
| KR20050013627A (ko) | 2005-02-04 |
| NO20045214L (no) | 2005-03-17 |
| CR7608A (es) | 2006-07-14 |
| US20040014798A1 (en) | 2004-01-22 |
| CN1665510A (zh) | 2005-09-07 |
| TW200400950A (en) | 2004-01-16 |
| JP2005535628A (ja) | 2005-11-24 |
| EP1531824A2 (en) | 2005-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200410407B (en) | Cyclothiocarbamative derivatives as PR modulators and use thereof for treatment of skin disorders | |
| RU2005101638A (ru) | Использование циклокарбаматных производных для лечения гормонзависимых состояний | |
| ES2386786T3 (es) | Método para tratar rubor cutáneo usando agonistas selectivos de receptores alpha-2-adrenérgicos. | |
| SK14762003A3 (sk) | Kožou prestupujúci prípravok obsahujúci selektívne inhibujúcu cyklooxygenázu-2 a jednosýtny alkohol | |
| JP2012087129A5 (ko) | ||
| PT1272186E (pt) | Combinações terapêuticas de agentes antiangiogénicos e antihipertensores | |
| US20040127531A1 (en) | Adhesive coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor | |
| TW200817378A (en) | Compositions and methods for treating or preventing glaucoma or progression thereof | |
| US20040126415A1 (en) | Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor | |
| TW200425915A (en) | Selective cyclooxygenase-2 inhibitor patch | |
| JP2022529661A (ja) | ジスキネジア治療薬 | |
| JPH07110806B2 (ja) | 脱毛症を治療するための組成物 | |
| RU2009127776A (ru) | Профилактическое или терапевтическое средство от алопеции | |
| BE1003002A6 (fr) | Composition a mettre en oeuvre pour le traitement de la calvitie, et procedes faisant usage de celle-ci. | |
| CA2824996A1 (en) | Compounds and methods for enhancing hair growth | |
| JP2004517853A5 (ko) | ||
| JPWO2021229152A5 (ko) | ||
| US20230201199A1 (en) | Therapeutic drug for dyskinesia | |
| AU3948699A (en) | Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation | |
| JP2024100696A (ja) | 育毛組成物 | |
| ES2286920B1 (es) | Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia. | |
| WO2021087074A1 (en) | Therapeutic formulations and uses thereof | |
| TW200403989A (en) | Methods and compositions for treatment of cancer pain | |
| MX2008002908A (es) | Inhibidores de ikk para el tratamiento de endometriosis | |
| Cimberle | Intracameral delivery of mydriatics shows promise, surgeons say |